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Abstract 
Introduction: We have previously shown that the isolated arginase 2 inhibitors have a pronounced endothelioprotective 
level. A strategy is proposed for the targeted search for isolated arginase 2 inhibitors among compounds of a phenolic 
nature. Received 3 compounds, isolated arginase inhibitors 2. As a result of the study, the acute toxicity of the compounds 
obtained was studied. 
Objectives of the study: to substantiate the choice of a phenolic compound, a selective arginase 2 inhibitor, which has the 
lowest acute toxicity among the compounds obtained. 
Methods: The experiment was conducted on laboratory mice of both sexes. Substance administered intragastrically. 
Observation of the animals was carried out for 14 days. 
Results: Summarizing the data obtained, it can be concluded that, after intragastric administration to mice, the investigated 
compounds of phenolic nature under laboratory ciphers KUD259, KUD972, KUD973 are slightly toxic. 
Conclusion: As the main candidate for the drug, it is advisable to consider the compound KUD972, which showed the 
highest LD50 values, and therefore has the lowest toxicity. 
Keywords: Acute Toxicity, Arginase Inhibitors 2, Compounds of Phenolic Nature. 
 
Introduction 
The basis of modern therapy of arterial 
hypertension and other cardiovascular diseases is the 
postulate of the need to correct endothelial 
dysfunction as an indicator of the adequacy of 
antihypertensive and other types of treatment. In fact, 
this means that lowering blood pressure (BP) without 
normalizing endothelial function cannot be considered 
a successfully solved clinical problem. 
"ADMA-eNOS" as a pharmacological target is of 
undoubted interest and has been the object of research 
by pharmacologists [1-6]. Studies have revealed the 
role of methylated derivatives of L-arginine 
monomethylarginine (L-NMMA) and asymmetric 
dimethylarginine (ADMA) as endogenous inhibitors 
of endothelial NO synthase (eNOS). 
Earlier studies have shown that preventing the 
accumulation and overcoming of inhibition of eNOS 
by an already established ADMA claims to be one of 
the ways to pharmacological correction endothelial 
dysfunction. Endothelium protective properties 
implemented by reducing the inhibitory effect of 
ADMA on eNOS agents such as L-arginine [7-8], 
tetrahydrobiopterin [9], non-selective arginase 
inhibitor L-norvaline [2, 5, 23], selective arginase II 
inhibitors [10-12, 25] and so forth, were 
experimentally confirmed. 
Thus, the urgent task of pharmacology is to search 
for substances that selectively affect the metabolism 
of nitric oxide, namely, selectively inhibit the enzyme 
Arginase 2. 
Currently, preclinical studies of toxicological 
safety, pharmacological activity, pharmacokinetics 
and bioequivalence are an integral part of the study of 
new drugs [13-22]. 
We have previously shown that selective arginase 
2 inhibitors have a pronounced endothelioprotective 
effect [12, 24]. A strategy for targeted search for 
selective arginase 2 inhibitors among compounds of 
phenolic nature has been proposed. Using the methods 
of computer simulation and high-tech screening, we 
obtained 3 compounds, selective arginase inhibitor 2. 
Objectives of the study: to substantiate the choice 
of a phenolic compound, a selective arginase 2 
inhibitor, which has the lowest acute toxicity among 
the compounds obtained. 
Materials and Methods 
Experiments on the study of acute toxicity were 
performed on laboratory mice of both sexes. The 
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studied compounds of phenolic nature KUD259, 
KUD972, KUD973 were administered intragastrically 
once to the animals using metal probes with 
atraumatic smooth olives at the end in five doses. The 
individual volume of the injected dose for each animal 
was calculated based on the value of body weight. 
Phenolic compounds under laboratory ciphers 
KUD259, KUD972, KUD973 were administered 
intragastrically once in doses of 500, 600, 700, 800 
and 900 mg / kg. In the study of "acute" toxicity, the 
clinical observation of each animal was carried out 
during the first hour after administration of the drug, 
daily for the next 14 days. The number of dead 
animals was counted during the experiment. 
Daily visually noted deviations in the consumption 
of food and water by animals in individual cells. At 
the opening of the dead animals visually inspected the 
internal organs, noted pathological changes in the 
color, size, location of organs. 
After completion of the experiment according to 
the method of B.M. Shtabsky counted LD50. 
Results 
Studies have shown that after intragastric 
administration to mice of the studied compounds of 
phenolic nature, in the indicated dosages, the death of 
animals was recorded. 
The death of animals occurred within 5-24 hours 
after priming. As a result of the study, the average 
lethal dose was calculated after intragastric 
administration of phenolic compounds to mice (Tables 
1–4). 
After the introduction of the studied compounds, 
the intensity of physical activity decreased on average 
after 1-2 hours, coordination of movements was 
disturbed, the skeletal muscle tone decreased, the 
reaction to tactile, painful, sonic and light stimuli. 
After 2-24 hours, the frequency of respiratory 
movements increased, and the depth decreased with a 
subsequent decrease in the frequency of respiratory 
movements. The state of the hair and skin patches, did 
not change during the entire observation period. The 
amount and consistency of fecal masses, frequency of 
urination and urine color did not change in all 
experimental groups during the entire observation 
period. The surviving animals remained sluggish and 
sedentary for 1-2 days hours after acute seeding. 
 
 
 
Table-1: Data characterizing the toxicity of compounds KUD259 phenolic nature in the study of "acute" 
toxicity in white mice after intragastric administration 
Group 
animal 
Dose, mg / kg Number of animals LD16 
mg/kg 
LD50 
mg/kg 
LD84 
mg/kg 
Total Fallen Survivors    
Control 0 10 0 10    
 
 
KUD259 
500 10 0 10 
677.3 813.3 949.3 
600 10 2 8 
700 10 2 8 
800 10 5 5 
900 10 7 3 
 
Table-2: Data characterizing the toxicity of compounds KUD972 of phenolic nature in the study of "acute" 
toxicity in white mice after intragastric administration 
Group 
animal 
Dose, mg / kg Number of animals LD16 
mg/kg 
LD50 
mg/kg 
LD84 
mg/kg 
Total Fallen Survivors    
Control 0 10 0 10    
 
 
KUD972 
500 10 0 10 
723.3 808.3 893.3 
600 10 0 10 
700 10 3 7 
800 10 4 6 
900 10 7 3 
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Table-3: Data characterizing the toxicity of compounds KUD973 phenolic nature in the study of "acute" 
toxicity in white mice after intragastric administration 
Group 
animal 
Dose, mg / kg Number of animals LD16 
mg/kg 
LD50 
mg/kg 
LD84 
mg/kg 
Total Fallen Survivors    
Control 0 10 0 10    
 
 
KUD973 
500 10 1 9 
556.2 604.8 653.3 
600 10 5 5 
700 10 8 2 
800 10 10 0 
900 10 10 0 
 
Upon the death of animals after the administration 
of the compounds under study, animals were dissected 
in all experimental groups for macroscopic assessment 
of the state of the internal organs. 
Visual examination of the thoracic and abdominal 
cavities of the dead animals of all groups of 
macroscopically distinguishable changes was not 
detected. There were no pathological contents in the 
thoracic and abdominal cavities. 
According to the results of the autopsy and 
macroscopic examination of the internal organs of the 
dead experimental animals that received the test 
compounds, no pathological changes were found: 
TONGUE. The tongue is clear. 
ESOPHAGUS. The mucosa of the esophagus gray, 
smooth, shiny. 
STOMACH. Stomach with well pronounced folds 
of the mucous. Gray mucus-wet, shiny. 
LIVER. The liver is dense with a smooth surface, 
on a section of red-brown color. 
THICK AND SLIM INTESTINE. The contents of 
the intestine corresponds to each of its sections. Its 
mucosa forms transverse folds, moist, gray. 
LYZY LITTLES, TRAHEAS, MAIN 
BRONCHES pink, smooth, moist, shiny. 
A HEART. The heart is rounded, well cut. Under 
the epicardium, the usual venous pattern of the 
location of the coronary vessels. The flaps are thin, 
translucent. The endocardium is smooth and shiny. 
The aorta is elastic, its intima is clean, smooth. 
KIDNEYS. The capsule of the kidneys is easily 
removed, under it the smooth surface of the kidneys, 
on the incision of the kidney of moderate blood 
supply with a clear division into layers. Mucous 
pelvis, bladder gray, moist, shiny. 
SPLEEN. The spleen with a smooth capsule, in the 
cut gray-red, pulp scraping does not. 
BRAIN. The brain shells are translucent, smooth, 
shiny. Brains of the brain are well defined. On a 
section the substance of the brain is wet, brilliant, with 
a symmetrical pattern of the structure. The vessels of 
the base of the brain are arranged symmetrically, with 
collapsed walls. 
The organs of the thoracic and abdominal cavities 
are located correctly. Cavities are free from liquids 
and adhesions. 
LUNGS. Light air, gray-pink color, covered with a 
thin pleura, lower lobes with uneven blood filling. 
ADRENAL. The adrenal glands are round, with a 
clear division of the parenchyma into the cortical and 
cerebral zones. 
Conclusion 
Summarizing the data obtained, it can be 
concluded that, when administered intracellularly to 
mice, the test compounds of phenolic nature under 
laboratory ciphers KUD259, KUD972 and KUD973 
are slightly toxic and belong to class IV toxicity. 
The most toxic compound with the lowest mean 
lethal dose is a phenolic compound under the 
laboratory cipher KUD973 (LD50 - 604.8 mg / kg). 
The least toxic compound with the highest average 
lethal dose is a phenolic compound under the 
laboratory coding KUD972 (LD50 - 808.3 mg / kg). 
Thus, as the main candidate for the drug, it is 
advisable to consider the compound KUD972, which 
showed the highest values of LD50, and therefore has 
the lowest toxicity. 
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